First Tracks Biotherapeutics earns outperform rating at Evercore, targeting immunology breakthroughs

Evercore ISI initiated coverage of First Tracks Biotherapeutics Inc. with an outperform rating.

The firm established a price target of $65.00 per share for the biotechnology company. Analysts cited the potential of the company's clinical-stage pipeline focused on immunology therapeutics for autoimmune and inflammatory diseases.

The $65.00 target represents a significant premium over recent trading levels. First Tracks Biotherapeutics currently maintains an average analyst rating of buy. FactSet data shows a mean price target of $71.82 across the street.